Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo.
about
The role of complement in monoclonal antibody-mediated protection against virulent Semliki Forest virusMonoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in miceRole of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodiesSecondary rearrangements and hypermutation generate sufficient B cell diversity to mount protective antiviral immunoglobulin responses.Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.Role of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection.Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesRaccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infectionEarly high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity.Replacement of the cytoplasmic domain alters sorting of a viral glycoprotein in polarized cellsHerpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.Duration of antigen availability influences the expansion and memory differentiation of T cells.Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice.Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.Antiviral immune responses in Itk-deficient mice.Amelioration of established Sendai viral pneumonia in the nude mouse using a monoclonal antibody to the virus fusion protein.Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread.T cell-independent antibody-mediated clearance of polyoma virus in T cell-deficient mice.Induction of long-lived germinal centers associated with persisting antigen after viral infection.CD4(+) T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability.Characterization of T-helper epitopes of the glycoprotein of vesicular stomatitis virusHemagglutinin-esterase-specific monoclonal antibodies alter the neuropathogenicity of mouse hepatitis virusMechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection.Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes.Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice.Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in miceProtective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitisProtection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein.Resistance to adenovirus infection after administration of Bordetella pertussis vaccine in miceVirus neutralization by germ-line vs. hypermutated antibodies.Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic methodTargeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis.Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune responseVirus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis.
P2860
Q27473170-EE67DF08-CFD4-4B2F-A88C-753561F233E3Q27486805-4C9D27D0-5B09-4D52-9BDA-A6C59F6B7B03Q27486933-8F481942-48EC-4AD5-B661-1897EE0D8C40Q30708822-3B075E49-6B57-4D70-A204-B9C478A9EF9EQ33800760-843C9F95-1719-4B37-8DDB-E71F4FA300E0Q33835246-28294B97-6500-4F94-A22F-17F6B21A8E8BQ33849224-28EDE892-C057-43D6-A605-386DA47CA044Q33925311-86A54ECB-3579-4671-93FA-1BD085FB0CD1Q34057711-684D6BE3-F147-438B-B759-A08770605534Q34106638-FEED9A78-A1D9-4128-B3C7-FE7173C7F3F7Q34599248-BFB537EE-278A-4147-B13D-23269BA5E9E4Q34617797-F75F07BC-EEC3-4044-8A6F-068988ABF9C1Q35058245-6640422F-B8AA-48C0-8573-9E6556FEDD2FQ35175877-01462088-8FD1-4D8E-BFFA-AD012CBEB996Q35182301-87BCB226-2269-4A2A-A213-2C63DF764C7DQ35531167-6DBC9D36-D9B7-4C3E-B68F-620A21EEFDD1Q35837415-C3D8D500-CF89-4D66-A648-12B61C565F68Q35851163-798868B9-5B03-446E-BFA7-1B96DCABB915Q35886309-E62DDD60-10CE-4F27-8961-8B2A3615E359Q35894892-0A12E2DE-216E-4A92-801C-818718B4A40DQ36089783-95BB153A-6B6B-45EB-BC0D-7B590A46DD4DQ36228781-2BF8DFFB-66D6-4179-8272-77596688E0B0Q36366211-8D4595A4-5B92-495B-9E98-2AF9AEA95390Q36366635-4F25A87D-A120-4B58-AEA0-41ED39D1D25DQ36368586-253C73BB-D06B-46F3-9210-5823FAA0F8E3Q36629062-70E095F0-621A-4981-88F6-364AFCAAB66EQ36697370-17B7009C-F677-44A0-AF91-B12E570A5BE6Q36698867-F9FEB1EA-4FC0-461A-92D7-FAC58F75FED7Q36783022-630CAD62-4BA9-4A8E-B91D-6689ABA8D3B2Q36802737-2B667E6D-F155-41CD-B7D8-B8E3CBBFE12DQ36864332-A491909D-95B0-41C4-9E42-A887778DEEC0Q36898964-9FB2F88D-BF5F-4E38-B422-1DC6A2485430Q36920330-C797126A-E3BB-4A49-B189-D11B3F8F3473Q37035495-2C4F2F6D-30CD-4846-BB9A-4E6CE278200FQ37414421-5086EADF-18F6-4E1D-9731-C9C3A99D1A06Q37643341-E05207D3-9F6C-4AEF-BEBF-B0EBE89EBB12Q38288045-6C754BA2-BA8D-41E6-B65A-94380EEC1BA2Q39592979-4EC87C1E-1D81-4DAF-B9A9-CE08044CEE56Q39789318-055E9795-2E05-41FA-B470-1EC12C3E1AECQ40126274-00A3CDDD-F95D-472C-AEAE-3345F81B361E
P2860
Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Protection against lethal vira ...... mechanisms of action in vivo.
@en
type
label
Protection against lethal vira ...... mechanisms of action in vivo.
@en
prefLabel
Protection against lethal vira ...... mechanisms of action in vivo.
@en
P2860
P1433
P1476
Protection against lethal vira ...... t mechanisms of action in vivo
@en
P2093
L Lefrancois
P2860
P304
P407
P577
1984-07-01T00:00:00Z